141 related articles for article (PubMed ID: 34398672)
1. Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development.
Wu X; Meng J; Yuan H; Zhong D; Yu J; Cao G; Liu X; Guo B; Chen Y; Li Y; Shi Y; Gordeev MF; Wu J; Zhang J
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0040921. PubMed ID: 34398672
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-Dihydropyridin-4-one catalyzed by non-P450 enzymes.
Meng J; Zhong D; Li L; Yuan Z; Yuan H; Xie C; Zhou J; Li C; Gordeev MF; Liu J; Chen X
Drug Metab Dispos; 2015 May; 43(5):646-59. PubMed ID: 25710940
[TBL] [Abstract][Full Text] [Related]
3. Preclinical toxicity evaluation of novel antibacterial contezolid acefosamil in rats and dogs.
Wang W; Li Z; Gordeev MF; Yuan H
J Appl Toxicol; 2024 May; 44(5):770-783. PubMed ID: 38237604
[TBL] [Abstract][Full Text] [Related]
4. Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity.
Wang W; Voss KM; Liu J; Gordeev MF
Chem Res Toxicol; 2021 May; 34(5):1348-1354. PubMed ID: 33913699
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of ultra-performance liquid chromatography-tandem mass spectrometric methods for simultaneous and rapid determination of contezolid and its major metabolite M2 in plasma and urine samples and its application to a study in subjects with moderate liver impairment.
Wang Y; Wu H; Wu J; Fan Y; Liu X; Li Y; Hu J; Zhang J; Guo B
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Feb; 1191():123129. PubMed ID: 35066246
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects.
Yang H; Jin Y; Wang H; Yuan H; Wang J; Li S; Hu Y; Yang H; Li X; Liang H; Wu J; Cao G; Zhang J
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0079623. PubMed ID: 37902402
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens.
Bulitta JB; Fang E; Stryjewski ME; Wang W; Atiee GJ; Stark JG; Hafkin B
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0140023. PubMed ID: 38415667
[TBL] [Abstract][Full Text] [Related]
8. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers.
Wu J; Cao G; Wu H; Chen Y; Guo B; Wu X; Yu J; Ni K; Qian J; Wang L; Wu J; Wang Y; Yuan H; Zhang J; Xi Y
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229495
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite-Resolution for Clinical Development.
Zheng J; Xin Y; Zhang J; Subramanian R; Murray BP; Whitney JA; Warr MR; Ling J; Moorehead L; Kwan E; Hemenway J; Smith BJ; Silverman JA
Drug Metab Dispos; 2018 Mar; 46(3):237-247. PubMed ID: 29311136
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacology and Utility of Contezolid in Chinese Patients with Complicated Skin and Soft-Tissue Infections.
Yuan H; Wu H; Zhang Y; Huang H; Li Y; Wu J; Cao G; Yu J; Guo B; Wu J; Yuan Z; Chen Y; Yang W; Wu X; Zhang J
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0243021. PubMed ID: 35575579
[TBL] [Abstract][Full Text] [Related]
12. A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity
Guo Q; Xu L; Tan F; Zhang Y; Fan J; Wang X; Zhang Z; Li B; Chu H
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0088921. PubMed ID: 34460305
[TBL] [Abstract][Full Text] [Related]
13. Advances in contezolid: novel oxazolidinone antibacterial in Gram-positive treatment.
Zhang GX; Liu TT; Ren AX; Liang WX; Yin H; Cai Y
Infection; 2024 Jun; 52(3):787-800. PubMed ID: 38717734
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
[TBL] [Abstract][Full Text] [Related]
15. Drug Degradation Caused by
Pi R; Chen X; Meng J; Liu Q; Chen Y; Bei C; Wang C; Gao Q
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0103422. PubMed ID: 36190243
[TBL] [Abstract][Full Text] [Related]
16.
Carvalhaes CG; Duncan LR; Wang W; Sader HS
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32778552
[TBL] [Abstract][Full Text] [Related]
17. Contezolid: First Approval.
Hoy SM
Drugs; 2021 Sep; 81(13):1587-1591. PubMed ID: 34365606
[TBL] [Abstract][Full Text] [Related]
18. Concentration of contezolid in cerebrospinal fluid and serum in a patient with tuberculous meningoencephalitis: A case report.
Guo W; Hu M; Xu N; Shangguan Y; Xia J; Hu W; Li X; Zhao Q; Xu K
Int J Antimicrob Agents; 2023 Aug; 62(2):106875. PubMed ID: 37276894
[TBL] [Abstract][Full Text] [Related]
19. Disposition and Metabolism of [
Ueno T; Ishida T; Aluri J; Suzuki M; Beuckmann CT; Kameyama T; Asakura S; Kusano K
Drug Metab Dispos; 2021 Jan; 49(1):31-38. PubMed ID: 33144331
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and Disposition of [
Bolleddula J; Chen H; Cohen L; Zhou X; Pusalkar S; Berger A; Sedarati F; Venkatakrishnan K; Chowdhury SK
Drug Metab Dispos; 2022 Jul; 50(7):989-997. PubMed ID: 35504658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
